Author: Kyowa Kirin

Posted Date:

May 6, 2026

CRYSVITA® Now Publicly Reimbursed for the Treatment of Adults with XLH in Four Provinces and Federal Non-Insured Health Benefits Program

Kyowa Kirin

May 6, 2026
Kyowa Kirin 重掌羅卡替尼單抗的研發和商業化項目，展現出致力解決異位性皮膚炎高度未獲滿足醫療需求的堅定承諾

Kyowa Kirin

February 25, 2026
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis

Kyowa Kirin

January 30, 2026